Advent Life Sciences

Investor type Venture Capital


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 50
Average round size
The average size of a deal this fund participated in
Portfolio companies 34
Rounds per year 3.85
Lead investments 11
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 13
Key employees 8

Areas of investment

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Medical
  • Biopharma

In 2010 was created Advent Life Sciences, which is appeared as VC. The company was established in Europe in United Kingdom. The main office of represented VC is situated in the London.

We also calculated 8 valuable employees in our database.

The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the Advent Life Sciences, startups are often financed by Advent Venture Partners, Index Ventures, Sofinnova Investments. The meaningful sponsors for the fund in investment in the same round are OrbiMed, Sofinnova Investments, SR One. In the next rounds fund is usually obtained by Gilde Healthcare, Advent Venture Partners, OrbiMed.

Among the most successful fund investment fields, there are Biopharma, Medical. The fund has exact preference in a number of founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little. Among the most popular portfolio startups of the fund, we may highlight Algeta, Acutus Medical, F2G. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States.

Opposing the other organizations, this Advent Life Sciences works on 2 percentage points more the average amount of lead investments. The high activity for fund was in 2017. Despite it in 2019 the fund had an activity. The usual things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in less than 2 deals per year. The top amount of exits for fund were in 2018. Speaking about the real fund results, this VC is 21 percentage points more often commits exit comparing to other organizations.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Advent Life Sciences:
Typical Co-investors
Advent Life Sciences is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Advent Life Sciences:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
AbbVie Chicago, Illinois, United States
Changshang Kunzhong -
Checkr California, San Francisco, United States
CloudWise Beijing, Beijing, China
Emaar Dubai, United Arab Emirates
Haniel Duisburg, Germany, Nordrhein-Westfalen
In Capital China, Hangzhou, Zhejiang
Journey Ventures Israel, Tel Aviv, Tel Aviv District
Krantz Holdings Beverly Hills, California, United States
Miele Venture -
Newlight Partners New York, New York, United States
Old Willow Partners Minnesota, Northfield, United States
Prisma Capital Brazil, Itaim, Minas Gerais
Redwood Venture Partners California, Los Altos, United States
Sofipaca Aix-en-Provence, France, Provence-Alpes-Côte d'Azur
SRB Management Dallas, Texas, United States
Swiss Investment group -
Trilogy Ventures China Beijing, Beijing, China
Urca Angels Brazil, São Paulo, Sao Paulo

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation


Life Science
$14M25 Apr 2022 Cambridge, Cambridgeshire, United Kingdom

Nalu Medical

Health Care
Medical Device
$104M17 Feb 2022 Carlsbad, California, United States


$80M02 Dec 2021 London, England, United Kingdom

NeRRe Therapeutics

Health Care
$27M07 Jul 2021 United Kingdom, England, United Kingdom

Aura Biosciences

Health Care
$80M22 Mar 2021 Cambridge, Massachusetts, United States

Amphista Therapeutics

$53M17 Mar 2021 Scotland

Highlight Therapeutics

Health Care
$26M04 Feb 2021 Spain, Valencian Community, Spain

Rappta Therapeutics

Life Science
$10M13 Oct 2020 Uusimaa


Health Care
$60M12 Aug 2020 Manchester, England, United Kingdom
Aura Biosciences Announces Oversubscribed $80 Million Financing

– Aura Biosciences closed an oversubscribed $80m financing.
– The financing was led by Matrix Capital Management and Surveyor Capital (a Citadel company) with participation from new investors, including Rock Springs Capital, Adage Capital Management LP and Velosity Capital.
– Existing investors Medicxi, Advent Life Sciences, Lundbeckfonden Ventures, Arix Bioscience, Chiesi Ventures, Ysios Capital and Columbus Venture Partners also participated in the round.

Amphista Therapeutics Raises $53M in Series B Funding

– Amphista Therapeutics from Glasgow, Scotland, UK, raised $53m in Series B funding.
– The round was co-led by Forbion and Gilde Healthcare with participation from Novartis Venture Fund, and Eli Lilly and Company, and existing investor BioMotiv and founding investor Advent Life Sciences.
– The new investment will be used to accelerate the company’s pipeline of potent and selective bifunctional molecules, known as ‘Amphistas’ to the clinic and to extend its proprietary TPD platform.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Advent Life Sciences?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: